Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Company Information
About this company
Key people
Adam Elsesser
Chairman of the Board, Chief Executive Officer
Shruthi Narayan
President
Maggie S. Yuen
Chief Financial Officer
Johanna Roberts
Executive Vice President, General Counsel, Secretary
Lambert Shiu
Chief Accounting Officer
Thomas C. Wilder
Presiding Independent Director
Arani Bose
Director
Harpreet S. Grewal
Independent Director
Janet Leeds
Independent Director
Bridget O'Rourke
Independent Director
Click to see more
Key facts
- Shares in issue39.16m
- EPICPEN
- ISINUS70975L1070
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$12.38bn
- Employees4,500
- ExchangeNew York Stock Exchange
- IndexS&P 400 Mid Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.